Drug Trial Radar · NCT07946913
A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Treatment With H1 Antihistamines
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
514
Planned (sponsor's estimate)
Start
Dec 7, 2026
Primary completion
Mar 24, 2028
Study completion Jan 26, 2029
Sponsor
- Lead sponsor
- Longbio PharmaIndustry
- Sponsor type
- Industry
- First posted
- Nov 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, active-controlled Phase III clinical study to evaluate the safety and efficacy of LP-003 injection in patients with chronic spontaneous urticaria who remain symptomatic despite treatment with H1 antihistamines.
Conditions
- Chronic Spontaneous Urticaria (CSU)
Interventions
LP-003 InjectionBiological
s.c. injection
OmalizumabBiological
s.c. injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in weekly Urticaria Activity Score (UAS7) at week 12Time frame: Week 12
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital
Beijing, China
The First Affiliated Hospital of China Medical University
Shenyang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.